• Phone: +1-631-791-1145
  • Email: sales@imarcgroup.com

Global Hyperlipidemia Drugs Market to Exhibit Moderate Growth, Impelled by Increasing Incidences of High Cholesterol

According to the latest report by IMARC Group, titled "Hyperlipidemia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025," the global hyperlipidemia drugs market grew at a CAGR of around 3% during 2014-2019. Hyperlipidemia is a lipid disorder that is caused due to the elevation of fat levels in the bloodstream of an individual. Commonly referred to as high cholesterol, it is caused due to a disorder in the synthesis as well as degradation of plasma lipoproteins. It can also be caused by improper lipid metabolism that can further lead to the development of numerous medical ailments, including obesity, diabetes, stroke, hypertension and cardiovascular diseases. While the primary form of hyperlipidemia is caused by genetic factors, secondary hyperlipidemia is induced by environmental influences. Several medications, such as statins, PCSK9 inhibitors and miscellaneous antihyperlipidemic agents, are widely being prescribed by healthcare professionals to maintain the cholesterol production levels in the liver.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Global Hyperlipidemia Drugs Market Trends:

The market is primarily driven by the increasing number of cases of hyperlipidemia on the global level. This can be accredited to the changing lifestyle patterns of the masses and their shifting dietary preferences. The increasing prevalence of the medical condition can also be attributed to the lack of exercise among individuals and the rising number of smokers across the globe. This, coupled with the escalating cases of obesity cases among the masses, is providing a thrust to the sales of hyperlipidemia drugs. There has also been a considerable rise in the geriatric population, which is susceptible to develop cardiovascular diseases and usually have high levels of cholesterol. This is acting as another major growth-inducing factor. Additionally, increasing awareness regarding the numerous treatment options available for combating hyperlipidemia is creating a positive outlook for the market. The market is further driven by the emergence of novel drugs that are expected to offer better efficacy and safety to the patients. The widespread utilization of these medicines is anticipated to minimize the incidences of inflammation and damage caused to the cells of the users, which will facilitate the uptake of these drugs. Some of the other factors contributing to the market growth include growing investments in the healthcare sector, development of the overall infrastructure and the increasing research and development (R&D) activities for developing innovative drugs. On account of the aforementioned factors, the market is anticipated to witness moderate growth during 2020-2025.

Market Summary:

  • On the basis of the drug type, the market has been divided into statins, bile acid sequestrants, cholesterol absorption inhibitors, PCSK9 inhibitors, fibric acid derivatives, and others.
  • Based on the end user, the market has been classified into hospitals, clinics and others.
  • On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players. Some of these players include Amgen Inc., AstraZeneca, Daiichi Sankyo Company Limited, Eli Lilly and Company, ESPERION Therapeutics, Inc., GlaxoSmithKline Pharmaceuticals Limited, Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi S.A.


About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us

IMARC Group

USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter : @imarcglobal

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )


Drop us an email at

sales@imarcgroup.com